Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Randall Goode

Anesthesiology Carson City, NV Medical Doctor

NPI 1891804712 CMS profile 40666

973 Mica Drive, Suite 201, Carson City, NV 89705

Open in the dashboard

General payments

$3,890

135 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Randall Goode of Carson City, NV is reported in the CMS Open Payments database as having received $3,890 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142 5
2024 General $198 13
2023 General $207 10
2022 General $728 28
2021 General $247 14
2020 General $345 16
2019 General $2,024 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Randall Goode
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Randall Goode were reported at $142. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Randall Goode Anesthesiology median Middle half National median
2019 $2,024 $72 $23–$151 $163
2020 $345 $36 $17–$120 $114
2021 $247 $49 $21–$135 $132
2022 $728 $52 $22–$144 $149
2023 $207 $53 $23–$143 $160
2024 $198 $55 $25–$150 $164
2025 $142 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,843 39 payments
  2. Medtronic USA, Inc. $570 25 payments
  3. Nevro Corp. $438 19 payments
  4. Medtronic, Inc. $397 16 payments
  5. Saluda Medical Americas, Inc. $202 13 payments
  6. Pfizer Inc. $88 5 payments
  7. AbbVie, Inc. $75 5 payments
  8. Nalu Medical, Inc. $39 2 payments
  9. Allergan Inc. $37 2 payments
  10. Collegium Pharmaceutical, Inc. $34 2 payments
  11. Other $166 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,040 129 payments
  2. Travel and Lodging $851 6 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $1,402 21 payments
  2. INTELLIS ADAPTIVESTIM $355 13 payments
  3. SYNCHROMED $299 6 payments
  4. PROCLAIM $288 11 payments
  5. Senza Spinal Cord Stimulation System $244 11 payments
  6. Omnia $164 6 payments
  7. INTELLIS $147 4 payments
  8. Evoke $137 10 payments
  9. RESTORE $125 15 payments
  10. Evoke SCS $65 3 payments
  11. Other $722 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

248

Median for Anesthesiology: 322

Drug cost

$4,760

Median for Anesthesiology: $8,738

Branded share of claims

37.9%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 67 $2,084
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $1,007
Pregabalin Generic 22 $808
Hydromorphone Hcl Generic 17 $255
Gabapentin Generic 22 $248
Tramadol Hcl Generic 19 $197
Tizanidine Hcl Generic 12 $113
Diazepam Generic 51 $39
Meloxicam Generic 11 $9

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$335,635

Of which drugs: $1,042

Medicare patients

621

Average age 74

Services billed

7,578

388 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Depression 23%
Ischemic heart disease 22%
Diabetes 21%
Chronic kidney disease 21%
Osteoporosis 20%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 112 734 $562
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 386 5,270 $470

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record